ArticleImmunity & ageing : I & A2008
Immunity, ageing and cancer.
Article in Immunity & ageing : I & A, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 3 syntheses or guidelines pooled it, 174 citations in OpenAlex.
- A systematic review and meta-analysis of incidence trends and risk factors for metachronous gastric lesions following endoscopic resection.Annals of medicine · 2025Pooled it
- Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method.Frontiers in endocrinology · 2023Pooled it
- Association of Personal Characteristics and Effectiveness of Immunotherapy in Late-Stage Non-Small Cell Lung Cancer: A Systematic Review.JNCI cancer spectrum · 2022Pooled it
- Oncoviruses at the Crossroads of Ageing and Cancer: Molecular Mechanisms and Key Signalling Pathways.Reviews in medical virology · 2026Review
- Active Vaccination Strategies for Alzheimer's Disease: An Expanded Review.European journal of immunology · 2026Review
- Phenotypic age acceleration and early-onset lung cancer: a case-control and prognostic cohort study involving multiple clinical centres with validation in the UK Biobank.EBioMedicine · 2026Article
- Therapeutic Advances in Targeting the Amyloid-β Pathway for Alzheimer's Disease.Brain sciences · 2025Review
- Review
- Nanoparticle-mediated delivery of herbal-derived natural products to modulate immunosenescence-induced drug resistance in cancer therapy: a comprehensive review.Frontiers in oncology · 2025Review
- Rare MSI-H hepatoid adenocarcinoma of the colon with BRAF V600E mutation achieving long-term disease-free survival after adjuvant envafolimab: a case report.Frontiers in immunology · 2025Article
- Article
- Global, regional, and national burden of 34 cancer groups across 204 countries and territories, 1990-2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.Frontiers in oncology · 2025Article
- Age-Specific Impact of Cribriform Pattern in Prostate Cancer Following Radical Prostatectomy.Clinical Medicine Insights. Oncology · 2025Article
- Identification of differentially expressed miRNAs involved in vascular aging reveals pathways associated with the endocrine hormone regulation.Biogerontology · 2024Article
- T Cell Resistance: On the Mechanisms of T Cell Non-activation.Immune network · 2024Review
- Aging-related biomarkers in testicular cancer survivors after different oncologic treatments.Cancer medicine · 2024Article
- mRNA Vaccine for Alzheimer's Disease: Pilot Study.Vaccines · 2024Article
- Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis.Haematologica · 2024Article
- Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Household air pollution and epigenetic aging in Xuanwei, China.Environment international · 2023Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compromised immunity contributes to the decreased ability of the elderly to control infectious disease and to their generally poor response to vaccination. It is controversial as to how far this phenomenon contributes to the well-known age-associated increase in the occurrence of many cancers in the elderly. However, should the immune system be important in controlling cancer, for which there is a great deal of evidence, it is logical to propose that dysfunctional immunity in the elderly would contribute to compromised immunosurveillance and increased cancer occurrence. The chronological age at which immunosenescence becomes clinically important is known to be influenced by many factors, including the pathogen load to which individuals are exposed throughout life. It is proposed here that the cancer antigen load may have a similar effect on "immune exhaustion" and that pathogen load and tumor load may act additively to accelerate immunosenescence. Understanding how and why immune responsiveness changes in humans as they age is essential for developing strategies to prevent or restore dysregulated immunity and assure healthy longevity, clearly possible only if cancer is avoided. Here, we provide an overview of the impact of age on human immune competence, emphasizing T-cell-dependent adaptive immunity, which is the most sensitive to ageing. This knowledge will pave the way for rational interventions to maintain or restore appropriate immune function not only in the elderly but also in the cancer patient.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.